Benchmarking biotech and pharmaceutical product development

Subjects

The biotech sector's record in originating high-priority medicines exceeds that of the pharmaceutical industry, its costs are lower and its products have comparable revenues.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    US Food and Drug Administration. Manual of Policies and Procedures. Review Designation Policy; Priority and Standard http://www.fda.gov/downloads/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/ucm082000.pdf (FDA, Washington, DC, 2013).

  2. 2

    US Congressional Budget Office. Research and Development within the Pharmaceutical Industry http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/76xx/doc7615/10–02-drugr-d.pdf (CBO, Washington, DC, 2006).

  3. 3

    US Food and Drug Administration. Guidance for Industry, Expedited Programs for Serious Conditions– Drugs and Biologics http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf (FDA, Washington, DC, 2014).

  4. 4

    Trusheim, M. Aitken, M.L. & Berndt, E.R. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? NBER Working Papers 01/2010 (National Bureau of Economic Research, Washington, DC, 2010).

    Google Scholar 

  5. 5

    Ernst & Young. Beyond Borders: Matter of Evidence http://www.ey.com/Publication/vwLUAssets/Beyond_borders/$FILE/Beyond_borders.pdf (E&Y, London, 2013).

  6. 6

    Kneller, R. Nat. Rev. Drug Discov. 9, 867–882 (2010).

    CAS  Article  Google Scholar 

  7. 7

    Munos, B. Nat. Rev. Drug Discov. 8, 959–968 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Ernst & Young. Beyond Borders. Global Biotechnology Industry Report (E&Y, London, 2013).

  9. 9

    Editors. Top 500 prescription drugs. PharmaLive, 5–14 (UBM Canon, Los Angeles, California, 2005).

  10. 10

    Editors. Top 500 prescription medicines. PharmaLive, 5–17 (UBM Canon, Los Angeles, California, 2006).

  11. 11

    Editors. Top 500 prescription medicines. PharmaLive, 5–16 (UBM Canon, Los Angeles, California, 2007).

  12. 12

    Editors. Top 500 prescription medicines. PharmaLive, 5–27 (UBM Canon, Los Angeles, California, 2008).

  13. 13

    Editors. Top 500 prescription medicines. PharmaLive, 5–40 (UBM Canon, Los Angeles, California, 2010).

  14. 14

    Editors. Top 500 prescription medicines. PharmaLive, 6–40 (UBM Canon, Los Angeles, California, 2011).

  15. 15

    Sellers, L.J. Top 50 Pharmaceutical Companies of 1999. Pharmaceutical Executive Magazine, 63–76 (Advanstar Communications, New York, NY, 2000).

    Google Scholar 

  16. 16

    Brichacek, A. Top 50 Pharmaceutical Companies of 2000. Pharmaceutical Executive Magazine (Advanstar Communications, New York, NY, 2001), 63–82.

  17. 17

    Sellers, L.J., Feighan, C. & Kelley, G. Top 50 Pharmaceutical Companies of 2001. Pharmaceutical Executive Magazine, 61–80 (Advanstar Communications, New York, NY, 2002).

    Google Scholar 

  18. 18

    Sellers, L.J. Fourth Annual Pharm Exec 50. Pharmaceutical Executive Magazine, 43–52 (Advanstar Communications, New York, NY, 2003).

    Google Scholar 

  19. 19

    Sellers, L.J. Pharm Exec 50. Pharmaceutical Executive Magazine, 61–70 (Advanstar Communications, New York, NY, 2004).

    Google Scholar 

  20. 20

    Pharm Exec Staff. Pharm Exec 50. Pharmaceutical Executive Magazine, 85–95 (Advanstar Communications, New York, NY, 2005).

  21. 21

    Pharm Exec Staff. Our 7th annual report on the world's top 50 pharmaceutical companies. Pharmaceutical Executive Magazine, 80–88 (Advanstar Communications, New York, NY, 2006).

  22. 22

    Pharm Exec Staff. Pharm Exec 50. Pharmaceutical Executive Magazine, 100–110 (Advanstar Communications, New York, NY, 2007).

  23. 23

    Pharm Exec Staff. Pharm Exec Top 50. Pharmaceutical Executive Magazine, 75–84 (Advanstar Communications, New York, NY, 2008).

  24. 24

    Pharm Exec Staff. The Pharm Exec 50. Pharmaceutical Executive Magazine, 69–78 (Advanstar Communications, New York, NY, 2009).

  25. 25

    Clinton, P. and Mozeson, M. Pharm Exec 50. Pharmaceutical Executive Magazine, 70–80 (Advanstar Communications, New York, NY, 2010).

    Google Scholar 

  26. 26

    Cacciotti, J. and Clinton, P. Pharm Exec 50. Pharmaceutical Executive Magazine, 42–56 (Advanstar Communications, New York, NY, 2011).

    Google Scholar 

  27. 27

    Clinton, P. and Cacciotti, J. Pharm Exec 50. Pharmaceutical Executive Magazine, 26–32 (Advanstar Communications, New York, NY, 2012).

    Google Scholar 

  28. 28

    Noor, W. and Kleinrock, M. Pharm Exec 50. Pharmaceutical Executive Magazine, 20–29 (Advanstar Communications, New York, NY, 2013).

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Donald L Drakeman.

Ethics declarations

Competing interests

The author has financial interests in numerous biotechnology companies.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Drakeman, D. Benchmarking biotech and pharmaceutical product development. Nat Biotechnol 32, 621–625 (2014). https://doi.org/10.1038/nbt.2947

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing